Diagnostic panels that use multiple biomarkers are better for diagnosing hepatocellular carcinoma (HCC) compared to single biomarkers, with models like ASAP and GALAD being evaluated for effectiveness.
In a study involving patients with chronic liver diseases (CLDs) from 14 hospitals in China, the ASAP model showed superior performance in detecting HCC compared to the GALAD model and individual biomarkers.
The ASAP model was particularly effective in identifying HCC across various types of CLDs and excelled in early-stage HCC detection, despite using one fewer biomarker than the GALAD model.